$0.06
+0.00 (+4.18%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PVCT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 expanded access · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 2.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| PV-10 in Combination With Pembrolizumab for Treatment of Metastatic MelanomaNCT02557321Safety and tolerability of the combination regimen assessed by adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Unknown status | Drug: PV-10, Pembrolizumab | Melanoma | 50 | May 2023actual | 2023-11-21 |
| A Study to Assess PV-10 Chemoablation of Cancer of the LiverNCT00986661Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10Open-label · Treatment | Phase 1 | Unknown status | Drug: PV-10 (10% rose bengal disodium) | Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer | 78 | Dec 2022 | 2022-11-02 |
| A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the LiverNCT02693067Number of Participants with Adverse EventsOpen-label · Treatment | Phase 1 | Unknown status | Drug: Rose bengal disodium | Neuroendocrine Tumors Metastatic to the Liver | 12 | 2021-09-01actual | 2023-02-08 |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous MelanomaNCT02288897results2022-01-19Progression-free Survival (PFS)Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Inadequate rate of enrollment | Drug: PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec | Cutaneous Melanoma | 20 | Apr 2019actual | 2022-01-19 |
| Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous TumorsNCT01260779expanded access | — | No longer available | Drug: PV-10 (10% rose bengal disodium) | Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy | — | — | 2016-07-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19